Extended Data Figure 7: Administration of the AMPAR antagonist, NBQX, prevents (2R,6R)-HNK-induced increases in gamma oscillations in vivo.
From: NMDAR inhibition-independent antidepressant actions of ketamine metabolites
a, Administration of (R,S)-KET, but not (2R,6R)- HNK, increased locomotor home-cage activity of mice. b–e, Neither (R,S)-KET nor (2R,6R)-HNK altered cortical alpha (b), beta (c), delta (d) or theta (e) oscillations in vivo. f–k, Pre-treatment with the AMPAR antagonist, NBQX, did not change the locomotor activity (f), alpha (g), beta (h), delta (j) or theta (k) oscillations, but it prevented (2R,6R)-HNK-induced increases of gamma oscillations in vivo (i). Data are mean ± s.e.m. *P < 0.05, **P < 0.01 (see Supplementary Table 1 for statistical analyses and n numbers).
